This document is intended for Investors and Investment Professionals 31 January 2025 Fact Sheet This is a marketing communication. Please refer to the prospectus of the fund and to the key investor information document before making any final investment decisions. ETF Index EquityETF (UCITS compliant) L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF ClassFund aim Fund facts The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index"). More information on the Index can be Fund size$18.5m found on page 2 of this document. Listing date 23 Jan 2018 Base currencyUSD Who is this fund for? Fund snapshot Domicile Ireland • This ETF is designed for investors looking to • Long-term allocation grow their money in an investment which can Long-term value in a pharmaceutical sub-sec- form part of their existing savings portfolio.Index tor that benefits from certain commercial Solactive Pharma Breakthrough Value • Although investors can take their money out and regulatory incentives Index Net TR USD at any time, this ETF may not be appropriate • High growth potential for those who plan to withdraw their moneyIndex ticker within five years. Aims to capture the future growth opportuni- SOLBIOT ty in orphan drugs • This fund is not designed for investors who Replication method cannot afford more than a minimal loss of • Leveraging industry expertise Physical - backed by equities their investment. An index tracking investment strategy that • If you do not understand the information in is supported by a team of pharmaceutical experts Availability this document, the key investor information document or the prospectus, we recommend ISA and SIPP eligible • Does it have a sustainable objective? that you seek additional information or UK Fund Reporting Status advice to help you decide if this ETF isThe Fund has a sustainable investment suitable for you. objective as it invests in companies which (i) contribute to social objectives, (ii) do not sig- Ongoing charge 0.49% nificantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.Performance (%) USD Accumulating class 40 20 1 month 6 months 1 year3 years 5 years 0 l NAV 4.35 ‑0.10 4.88 ‑12.17 ‑0.13 -20 l Index 4.38 0.15 5.45 ‑10.99 2.13 -40 Relative ‑0.03 ‑0.25 ‑0.57 ‑1.18 ‑2.26 Jan 21 Jan 22 Jan 23 Jan 24 Jan 25Rolling 12-month performance To 31 December202420232022202120202019 2018 20172016 2015 NAV ‑4.81 ‑10.26 ‑7.26 ‑3.85 27.09 12.67 -—-—-—-— Index ‑4.29 ‑9.94 ‑6.86 ‑3.44 27.73 13.45 -—-—-—-— Relative ‑0.52 ‑0.32 ‑0.40 ‑0.41 ‑0.64 ‑0.78 -—-—-—-— Performance for the USD Accumulating ETF class, listed on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF. Past performance is not a guide to the future. Fact Sheet L&G Pharma Breakthrough UCITS ETF | USD Accumulating ETF Class 31 January 2025 Index breakdown The breakdowns below relate to the Index. The ETF’s portfolio may deviate from the below. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. l Top 10 constituents 35.8% l Rest of Index 64.2% Number of constituents in Index 37Currency (%) Sector (%) Top 10 constituents (%) l USD 64.2l Health Care98.1 PharmaMar 5.9 l JPY 13.9l Materials 1.9 Xeris Biopharma 3.9 l EUR 8.8Bristol Myers Squibb3.4 l HKD 3.0argenx 3.4 l SEK 2.8BeiGene 3.3 l AUD 2.4Jazz Pharmaceuticals3.2 l DKK 2.0Ligand Pharmaceuticals 3.2 l KRW 1.9Catalyst Pharmaceuticals3.2 l CHF 1.0Supernus Pharmaceuticals3.2 Royalty Pharma 3.1Country (%) 🇺🇸 United States 57.9 🇯🇵 Japan 13.9 🇪🇸 Spain 5.9 🇮🇪 Ireland 3.2 🇬🇧 United Kingdom 3.1 🇰🇾 Cayman Islands 3.0 🇫🇷 France 2.9 🇸🇪 Sweden 2.8 🇦🇺 Australia 2.4 🌐 Other5.0Index description The Index is comprised of bio-technology companies which are publicly traded on various Index fund stock exchanges around the world that are actively engaged in the research, development management team and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible The Index Fund Management for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the totalteam comprises 25 fund market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently managers, supported by two analysts. “liquid” (a measure of how actively its shares are traded on a daily basis). Management oversight is provided by the Global Head of Index Funds. The team The universe of companies out of which the Index selection is made is refreshed annually in has average industry experience of 15 April. However, the Index is reconstituted semi-annually in April and October in accordance years, of which seven years has been at with the full selection criteria and all companies are equally weighted within the Index. On a LGIM, and is focused on achieving the monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of equally important objectives of close the Index, the weights of all companies are adjusted so that they are again equally weighted tracking and maximising returns. within the Index. This document is intended for Investors and Investment Professionals. 2 of 5 Fact Sheet L&G Pharma Breakthrough UCITS ETF | USD Accumulating ETF Class 31 January 2025 Key risksRisk and reward profile • The value of an investment and any income taken from it is not guaranteed and can go down as well as up; you may not get back the amount you originally invested. 1 2 3 4567 • An investment in the ETF involves a significant degree of risk. Any decision to invest should beLower risk Higher risk based on the information contained in the relevant prospectus. Prospective investors should Potentially lower rewards Potentially higher rewards obtain their own independent accounting, tax and legal advice and should consult their own professional advisers to ascertain the suitability of the ETF as an investment.This ETF is rated 6 due to the nature of • The value of the shares in the ETF is directly affected by increases and decreases in the value its investments and its risks. of the Index. Accordingly the value of a share in the ETF may go up or down and a shareholderThe rating is calculated based on may lose some or the entire amount invested.historical data and may not be a reliable • The ETF's ability to closely track the Index will be affected by its ability to purchase and/or sell indication of the ETF’s future risk profile. the Index constituents and any legal or regulatory restrictions or disruptions affecting them.The risk category may shift over time. • The ETF's ability to closely track the Index will also be affected by transaction costs and taxes incurred when adjusting its investment portfolio generally and/or to mirror any periodic The lowest category on the above scaledoes not mean “risk free”. adjustments to the constituents of the Index. There can be no certainty that ETF shares can always be bought or sold on a stock exchange or that the market price at which the ETF shares may be traded on a stock exchange will reflect the performance of the Index. • The ETF is subject to the risk that third party service providers (such as a bank entering into swaps with the ETF or the ETF's depositary) may go bankrupt or fail to pay money due to the ETF or return property belonging to the ETF. • As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole. • Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of: (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercially viability. Additionally, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of such companies. Such factors could lead to a decline in the value of the companies represented in the Index and therefore the ETF. • There is no capital guarantee or protection on the value of the ETF. Investors can lose all the capital invested in the ETF. • Please refer to the “Risk Factors” section of the Issuer’s Prospectus and the Fund Supplement. • This Fund may have underlying investments that are valued in currencies that are different from the currency of this share class, in which case exchange rate fluctuations will impact the value of your investment. In addition, the return in the currency of this share class may be different to the return in your own currency. For more information, please refer to the key investor information document on our website. Trading information Country registration ExchangeCurrency ISIN SEDOL Ticker Bloomberg AustriaDenmark Finland London Stock Exchange USDIE00BF0H7608 BF0H760 BIOTBIOT LN France Germany Ireland London Stock Exchange GBPIE00BF0H7608 BDT5BG9 BIGTBIGT LN Borsa Italiana EURIE00BF0H7608 BDVP3M7 BIOTBIOT IM Italy Luxembourg Netherlands Deutsche Börse EURIE00BF0H7608 BDVP3N8 ETLIETLI GY Norway SpainSweden Euronext Amsterdam EURIE00BF0H7608 BDVP3P0 BIOTBIOT NA SIX Swiss Exchange CHFIE00BF0H7608 BMG6942 BIOTBIOT SW SwitzerlandUnited Kingdom The currency shown is the trading currency of the listing. This document is intended for Investors and Investment Professionals. 3 of 5 Fact Sheet L&G Pharma Breakthrough UCITS ETF | USD Accumulating ETF Class31 January 2025 Important information A copy of the English version of the prospectus from us upon request. For further information includes, inter alia, information on certain risks of the Fund is available on LGIM Fund Centreon our products (including the product associated with an investment. The price of any and may also be obtained from Legal & General prospectuses), please visit our website. securities may go up or down and an investor Investment Management, 2 Dublin Landings, The shares (the “Shares”) discussed in thismay not get back the amount invested. Investors Office 1-W-131, North Dock, Dublin 1, Ireland. document are issued in relation to the relevantshould only invest in a currency-hedged share Where required under national rules, the keysub-fund (or share class(es) thereof) describedclass if they are willing to forego potential gains investor information document will also be in this document (together, the “Fund”). from appreciations in the currencies in which available in the local language of the relevantthe Fund’s assets are denominated against the EEA Member State. A summary of investor Copyright © 2025 Legal & General. This currency of denomination of the relevant hedged rights associated with an investment in the document is subject to copyright. Any share class. Currency hedging employed with Fund shall be available from www.lgim.com/ unauthorised use is strictly prohibited. All rightsrespect to the hedged share classes aims to investor_rights are reserved. reduce currency risk rather than to eliminate it We are also obliged to disclose that theNo investment advice: We are required to clarify completely. Investors should also refer to the Management Company has the right to that we are not acting for you in any way in risk factor entitled “Currency” in the section of terminate the arrangements made for relation to the investment or investment activity the Prospectus entitled “Risk Factors”. marketing. to which this document relates. In particular, we Prospectus: Investors should refer to the will not provide any investment services to yousection entitled “Risk Factors” in the Fund’s A decision may be taken at any time to and or advise you on the merits of, or make any terminate the arrangements made for theprospectus for further details of these and recommendation to you in relation to, the termsother risks associated with an investment in marketing of the Fund in any EEA Member of any transaction. None of our representatives State in which it is currently marketed. In such the Shares. The information in this document is are authorised to behave in any way which designed solely for use in the relevant countries circumstances, Shareholders in the affected EEA would lead you to believe otherwise. We are not, Member State will be notified of this decision in which the Fund has been registered for public therefore, responsible for providing you with the distribution and is not intended for residents and will be provided with the opportunity toprotections afforded to some of our clients and redeem their shareholding in the Fund free of any other countries. The distribution of the you should seek your own independent legal,prospectus and the offering, sale and delivery of of any charges or deductions for at least 30investment and tax or other advice as you see working days from the date of such notification. Shares in other jurisdictions may be restricted fit. by law. This is a marketing communication. Please refer United States information: This document to the prospectus of the Fund and to the KIID For United Kingdom investors: The Fund is a is not, and under no circumstances is to berecognised scheme under section 264 of the before making any final investment decisions. construed as, an advertisement or any otherFinancial Services and Markets Act 2000 and so In the United Kingdom and outside the step in furtherance of a public offering of shares the prospectus may be distributed to investors European Economic Area, this document in the United States or any province or territory in the United Kingdom. Copies of all documents is issued by Legal & General Investment thereof, where none of the Fund or the Shares (i.e. the prospectus, the key investor information Management Limited, authorised and regulatedare authorised or registered for distribution document, the latest annual audited report and by the Financial Conduct Authority, No. 119272. and where no prospectus of the Fund hasfinancial statements and semi-annual unaudited Registered in England and Wales No. 02091894been filed with any securities commission or report and financial statements and the with registered office at One Coleman Street, regulatory authority. Neither this document norconstitution) are available in the United Kingdom London, EC2R 5AA. any copy hereof should be taken, transmitted orfrom www.lgim.com. In the European Economic Area, this documentdistributed (directly or indirectly) into the United States. Neither the Fund nor any of the Shares For Austrian investors: Investors should base is issued by LGIM Managers (Europe) Limited, their investment decision only on the relevant authorised by the Central Bank of Ireland ashave been or will be registered under the United States Securities Act of 1933 or the Investmentprospectus, the Key Information Document, any a UCITS management company (pursuant supplements or addenda thereto, copies of the to European Communities (Undertakings for Company Act of 1940 or qualified under any applicable state securities statutes. Memorandum and Articles of Association and Collective Investment in Transferable Securities) the annual and semi-annual report, which can Regulations, 2011 (S.I. No. 352 of 2011), asNo guarantee of accuracy: This documentbe obtained free of charge upon request at the amended) and as an alternative investment may contain independent market commentary Paying and Information Agent in Austria, Erste fund manager with “top up” permissions whichprepared by us based on publicly available Bank der oesterreichischen Sparkassen AG, enable the firm to carry out certain additional information. We do not warrant, guarantee or Graben 21, 1010 Wien, Österreich and on www. MiFID investment services (pursuant to the otherwise confirm the accuracy or correctness lgim.com. European Union (Alternative Investment Fund of any information contained herein and any Managers) Regulations 2013 (S.I. No. 257 of opinions related to product or market activity For Dutch investors: The Fund has been 2013), as amended). Registered in Ireland with may change. Any third party data providers registered with the Netherlands Authority for the the Companies Registration Office (No. 609677). used to source the information in this documentFinancial Markets following the UCITS passport- Registered Office: 70 Sir John Rogerson’s Quay, make no warranties or claims of any kind procedure pursuant to section 2:72 of the Dutch Dublin, 2, Ireland. Regulated by the Central Bank relating to such data. Financial Supervision Act. of Ireland (No. C173733). Historical performance is no indication of For French investors: In France, this material is LGIM Managers (Europe) Limited operates a future performance: Any historical performance intended exclusively for professional investors branch network in the European Economic Area, included in this document may be based on (as defined under the MIFID) investing for which is subject to supervision by the Central back testing. Back testing is the process of their own account and this material may not Bank of Ireland. In Italy, the branch office of evaluating an investment strategy by applying in any way be distributed to the public. The LGIM Managers (Europe) Limited is subject it to historical data to simulate what the Fund is a UCITS governed by Irish legislation to limited supervision by the Commissione performance of such strategy would have been. and approved by the Central Bank of Ireland Nazionale per le società e la Borsa (“CONSOB”) However, back tested performance is purely as UCITS compliant with European regulations and is registered with Banca d’Italia (no. hypothetical and is provided in this document although may not have to comply with the 23978.0) with registered office at Piazza della solely for informational purposes. Back tested same rules as those applicable to a similar Repubblica 3, Milano 20121, (Companies’ data does not represent actual performance product approved in France. The Fund has Register no. MI - 2557936). In Germany, the and should not be interpreted as an indication of been registered for marketing in France by branch office of LGIM Managers (Europe) actual or future performance. the Authority Financial Markets (Autorité des Limited is subject to limited supervision by the Marchés Financiers) and may be distributed to No offer for sale: The information contained ininvestors in France. Copies of all documents German Federal Financial Supervisory Authority this document is neither an offer for sale nor (“BaFin”). In the Netherlands, the branch office (i.e. the prospectus, any supplements or a solicitation of an offer to buy securities. This addenda thereto, the latest annual reports, the of LGIM Managers (Europe) Limited is subjectdocument should not be used as the basis for to limited supervision by the Dutch Authority memorandum of incorporation and articles of any investment decision. association and Key Information Document) are for the Financial Markets (“AFM“) and it is included in the register held by the AFM andRisk Warnings: The Shares are products available in France, free of charge, at the French registered with the trade register of the Chamber involving a significant degree of risk and may Centralizing Agent, Société Générale, Securities of Commerce under number 74481231. not be suitable for all types of investor. Any Services, at 1-5 rue du Débarcadère, 92700 Details about the full extent of our relevant decision to invest should be based on the Colombes - France. Any subscription for Shares authorisations and permissions are availableinformation contained in the prospectus of the Fund (or any supplements thereto) which This document is intended for Investors and Investment Professionals. 4 of 5 Fact Sheet L&G Pharma Breakthrough UCITS ETF | USD Accumulating ETF Class31 January 2025 of the Fund will be made on the basis of the legal requirements designed to promote the terms of the prospectus and any supplements independence of investment research and is not or addenda thereto. subject to any prohibition on dealing ahead of For German investors: Investors should base the dissemination of investment research. their investment decision only on the relevantFor Norwegian Investors: The Fund has been prospectus and the Key Information Document. registered with the Financial Supervisory The offering of the Shares of the Fund hasAuthority of Norway (Finanstilsynet), and may been notified to the German Financial Servicesbe marketed and sold to professional investors Supervisory Authority (BaFin) in accordance in Norway. We are one of Europe’s largest asset with section 310 of the German Investmentmanagers and a major global investor, with For Swiss investors: The Fund described in thisassets under management of £1,122.2 billion Code (KAGB). The Key Information Document document will be distributed in Switzerland (in the German language), the prospectus, any(as at 30 June 2024). We work with a wide exclusively to qualified investors as defined supplements or addenda thereto, copies ofrange of global clients, including pension in the Swiss Collective Investment Schemes the Memorandum and Articles of AssociationAct and its implementing ordinance, though schemes, sovereign wealth funds, fund and the annual and semi-annual report, canthose qualified investors may themselves distributors and retail investors. be obtained free of charge upon request atrecommend the fund to end investors. The Source: LGIM internal data as at 30 June the Paying and Information Agent in Germany, representative and paying agent in Switzerland 2024. The AUM disclosed aggregates the HSBC Trinkaus & Burkhardt AG, Königsallee is State Street Bank International GmbH, assets managed by LGIM in the UK, LGIMA in 21-23, 40212 Düsseldorf and on www.lgim. Munich, Zurich Branch, Beethovenstrasse 19,the US and LGIM Asia in Hong Kong (2018- com. The current offering and redemption prices 8027 Zurich, Switzerland. The prospectus, as well as the net asset value and possible 2019 only). The AUM includes the value of the key information document, the articles of securities and derivatives positions. notifications of the investors can also beassociation and the annual and semi-annual requested free of charge at the same address. reports relating to the Fund are available free of This document is a marketing communicationcharge from the representative in Switzerland. within the meaning of Section 63 para. 6 of the As regards distribution in Switzerland, the German Securities Trading Act (WpHG). It is not place of jurisdiction and performance is at the investment research within the meaning of Art.registered seat of the representative. 36 of the Commission Delegated Regulation (EU) 2017/565 and therefore does not meet all Contact us Call 0345 070 8684 Email fundsales@lgim.com Visit lgim.com Lines are open Monday to Friday 8.30am to 6.00pm. We may record and monitor calls. Call charges will vary. Index disclaimer The L&G Pharma Breakthrough UCITS ETF (the “ETF”) is not sponsored, promoted, sold or supported by Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect. The Solactive Pharma Breakthrough Value Index (the “Index”) is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Legal & General UCITS ETF Plc, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the ETF. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein. Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the ETF, constitutes a recommendation by Solactive AG to invest capital in said ETF nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this ETF. In no event shall Solactive AG have any liability for any lost profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof. This document is intended for Investors and Investment Professionals. 5 of 5